Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Jan 17/23 Q & A session

<< Previous

Bullboard Posts

Next >>

Comment by SironaInvestoron Jan 16, 2023 2:30pm

245 Views

Post# 35226199

RE:Jan 17/23 Q & A session

I do not expect anything to be fair. Mostly I'm interested about Howards reply if someone raises the questions about a new CEO. As this has been assumed from PRC Partners, Howard's needs to be relatively clear about the relationship with PRC Partners. They mentioned that Management actively seeking after a new CEO. And it was the Sirona management who told it to PRC partners.
So did this interview between PRC and Sirona Management really happened?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario